Regenerative medicine venturing at the university-industry boundary: implications for institutions, entrepreneurs, and industry

Bock, A. J. and Johnson, D. (2018) Regenerative medicine venturing at the university-industry boundary: implications for institutions, entrepreneurs, and industry. In: Schmuck, E. G., Hematti, P. and Raval, A. N. (eds.) Cardiac Extracellular Matrix: Fundamental Science to Clinical Applications. Series: Advances in experimental medicine and biology (1098). Springer: Cham, Switzerland, pp. 213-236. ISBN 9783319974200 (doi:10.1007/978-3-319-97421-7_12)

Full text not currently available from Enlighten.

Abstract

Regenerative medicine research at university laboratories has outpaced commercial activity. Legal, regulatory, funding, technological, and operational uncertainty have slowed market entry of regenerative medicine treatments. As a result, commercial development has often been led by entrepreneurial ventures rather than large biopharma firms. Translating regenerative medicine across the university-industry boundary links academic scientists, technology transfer organizations, funders, and entrepreneurs. Conflicting motivations among the participants may significantly hinder these efforts. Unproven downstream business models for regenerative medicine delivery further complicate the entrepreneurial process. This chapter explores the challenges associated with entrepreneurial activity commercializing regenerative medicine science developed at research institutions.

Item Type:Book Sections
Status:Published
Glasgow Author(s) Enlighten ID:Johnson, Dr David
Authors: Bock, A. J., and Johnson, D.
College/School:College of Social Sciences > Adam Smith Business School > Management
Publisher:Springer
ISBN:9783319974200
Published Online:21 September 2018

University Staff: Request a correction | Enlighten Editors: Update this record